Colossal Biosciences
Dallas-based biotechnology and genetic engineering company working on de-extinction of species such as the woolly mammoth, dire wolf, thylacine, dodo and moa. It has also developed a 3D-printed artificial egg system for avian embryo development.
- CEO / Founder
- Ben Lamm
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $555M
- Latest Round
- Series C
- Key Investors
- TWG Global; Thomas Tull; Draper Associates; Breyer Capital; Winklevoss Capital Management; Animoca Brands; Bold Capital; Jazz Ventures
Technology & Products
Key Products
De-extinction programs (woolly mammoth, dire wolf, thylacine, dodo, moa, bluebuck); artificial egg system with a rigid hexagonal support cup and a semi-permeable silicone gas-exchange membrane (prototypes printed on Formlabs Form 4 in BioMed Black resin, final iterations in titanium); avian primordial germ cell culture technology; Colossal Foundation; spinouts Form Bio and Astromech.
Technological Advantage
Large capital base (over $555M raised) and a team of about 170 scientists plus advisors; co-founded by Harvard geneticist George Church; artificial egg platform uses AM for geometric control and scales from hummingbird-sized to moa-sized eggs.
Differentiation
Value Proposition
Develops genetic engineering, reproductive and enabling technologies, including artificial incubation hardware, to revive extinct species and support conservation of endangered ones.
How They Differentiate
Venture-backed, for-profit model with a large capital base and spinout monetization strategy, in contrast to non-profit and academic efforts; develops enabling hardware such as 3D-printed artificial eggs in-house.
Market & Competition
Target Customers
Conservation organizations, governments and research institutions. Commercial value is captured through technology spinouts such as Form Bio (software) and Astromech (AI).
Industry Verticals
Biotechnology; conservation biology; developmental biology; avian/poultry science; genomics
Competitors
Revive & Restore (non-profit genetic rescue); University of Melbourne TIGRR Lab (academic thylacine de-extinction)
Growth & Milestones
Growth Metrics
About 170 employees (2025). Valuation rose from over $1B (2023) to $10.2B (January 2025) and $10.32B (September 2025).
Major Milestones
2021-09: Launched with $15M seed; 2022-03: $60M Series A; 2022-09: Spun out Form Bio; 2023-01: $150M Series B; 2024-10: Launched Colossal Foundation; 2025-01: $200M Series C; 2025-09: $120M Series C extension and pigeon PGC breakthrough; 2025-11: Acquired Viagen; 2026-05: Hatched 26 chickens from 3D-printed artificial eggs.
Recent coverage of Colossal Biosciences
AM patents
AM-relevant patents linked to this company.
- Patents
- 1
- Granted
- 0
- Families
- 1
Leading domains: process (1)
Filings by year: 2022: 1
- THREE-DIMENSIONAL CO-CULTURE SYSTEM FOR EMBRYOS CULTURED IN VITRO AND USES THEREOF2024081614 · WO